Nadim Ahmed
Known title: President and CEOCIK: 0001731193
Nadim Ahmed's purchase track record
Nadim Ahmed has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/6/2022 | CGEM | $100K | +3.3% | -5.5% | -3.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CGEM | ▼ Sell | Open Market | 13,515 | $196K | 2/24/2026 | View on chart |
| CGEM | ▼ Sell | Open Market | 16,381 | $223K | 2/20/2026 | View on chart |
| CGEM | ▼ Sell | Open Market | 9,922 | $99K | 12/23/2025 | View on chart |
| CGEM | ▼ Sell | Open Market | 12,529 | $107K | 2/25/2025 | View on chart |
| CGEM | ▲ Buy | Grant | 180,000 | $0 | 2/19/2025 | View on chart |
| CGEM | ▼ Sell | Open Market | 8,400 | $100K | 12/24/2024 | View on chart |
| CGEM | ▲ Buy | Grant | 160,000 | $0 | 2/22/2024 | View on chart |
| CGEM | ▼ Sell | Open Market | 4,272 | $39K | 12/26/2023 | View on chart |
| CGEM | ▼ Sell | Open Market | 759 | $9K | 6/28/2023 | View on chart |
| CGEM | ▼ Sell | Open Market | 707 | $6K | 5/23/2023 | View on chart |
| CGEM | ▼ Sell | Open Market | 716 | $8K | 4/25/2023 | View on chart |
| CGEM | ▼ Sell | Open Market | 706 | $7K | 3/23/2023 | View on chart |
| CGEM | ▲ Buy | Grant | 109,000 | $0 | 2/22/2023 | View on chart |
| CGEM | ▲ Buy | Grant | 1,620 | $18K | 6/30/2022 | View on chart |
| CGEM | ▲ Buy | Open Market | 8,090 | $100K | 6/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cullinan delays arthritis data update to December
Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.
Cullinan delays arthritis data update to December. Cullinan Therapeutics announced it will delay its arthritis data update for zipalertinib to December due to ongoing safety concerns. This decision follows the release of strong Phase 3 lung cancer data, which initially saw the stock drop 18.2%. The company also confirmed plans for Q4 2026 updates across three T cell engager programs.